ArticleCureus2025
Efficacy of External Siddha Pharmacotherapy for Giant Acrochordon: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant acrochordons, commonly referred to as skin tags, are benign, pedunculated lesions often linked to conditions such as obesity, diabetes, and metabolic syndrome. While these lesions are generally harmless, they can lead to discomfort or cosmetic concerns, prompting individuals to seek treatment. Traditional methods, including excision and cryotherapy, are frequently employed but come with certain risks. This study explores the use of Pachaieruvai, a traditional Siddha medicine, as an alternative treatment option. The subject of this report was a 50-year-old male who had a large skin tag on his gluteal region that had been growing for 15 years. Opting for Pachaieruvai over surgery, he applied the topical preparation for 10 days. Remarkably, the lesion was completely resolved within 15 days, and follow-up evaluations at two weeks, three weeks, and six months showed no recurrence or complications. Pachaieruvai comprises five ingredients recognized for their cytotoxic properties, including arsenic trioxide and copper sulfate, which may assist in targeting abnormal cell growth. However, the study's small sample size, absence of controlled trials, and potential safety concerns regarding arsenic necessitate further research to validate its efficacy and establish standardized treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.